Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

Based on 1133 first isolates · ED · Cystitis (lower UTI) · 2025-08-17 → 2026-08-16
Emergency department
Per-organism detail: ED urine resistance view →
Narrowest option reaching 80 % coverage, no active warning
nitrofurantoin 83 % (81 %–85 %)
No tissue or blood levels: cystitis only.
Not covered: Proteus mirabilis (7 %), Pseudomonas aeruginosa (6 %), Klebsiella pneumoniae (3 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
meropenem MEM
trend · Escherichia coli reserve
85 %
88 %
n = 112
nitrofurantoin NIT
trend · Escherichia coli lower UTI only
83 %
79 %
n = 112
piperacillin-tazobactam TZP
trend · Escherichia coli broad spectrum
81 %
88 %
n = 112
ciprofloxacin CIP
trend · Escherichia coli
79 %
83 %
n = 112
mecillinam MEC
trend · Escherichia coli lower UTI only
77 %
79 %
n = 112
ceftriaxone CRO
trend · Escherichia coli
76 %
79 %
n = 112
trimethoprim TMP
trend · Escherichia coli lower UTI only
71 %
67 %
n = 112
71 %
76 %
n = 112
53 %
58 %
n = 112
vancomycin VAN
trend · Enterococcus faecalis Gram-positive only
13 %
11 %
n = 112
5 %
8 %
n = 112
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
2 %
0 %
n = 112

Most likely organisms for this profile

Escherichia coli
55 %
Enterococcus faecalis
10 %
Klebsiella pneumoniae
10 %
Proteus mirabilis
7 %
Pseudomonas aeruginosa
6 %
Citrobacter freundii
4 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.